Fenbufen

Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with analgetic and antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC50s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor[1][2][3][4][5].

Product Specifications

CAS Number

[36330-85-5]

Product Name Alternative

CL-82204

UNSPSC

12352005

Hazard Statement

H301

Target

Caspase; COX

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Fenbufen.html

Purity

99.33

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

O=C(O)CCC(C1=CC=C(C2=CC=CC=C2)C=C1)=O

Molecular Formula

C16H14O3

Molecular Weight

254.28

Precautions

H301

References & Citations

[1]A E Sloboda, et al. The pharmacological properties of fenbufen. A review. Arzneimittelforschung. 1980;30 (4A) :716-21.|[2]R G Child, et al. Fenbufen, a new anti-inflammatory analgesic: synthesis and structure-activity relationships of analogs, J Pharm Sci. 1977 Apr;66 (4) :466-76.|[3]A E Sloboda, et al. The pharmacology of fenbufen, 3- (4-biphenylylcarbonyl) propionic acid, and 4-biphenylacetic acid, interesting antiinflammatory-analgesic agents. Inflammation. 1976 Dec;1 (4) :415-38.|[4]Asif Husain, et al. Fenbufen based 3-[5- (substituted aryl) -1,3,4-oxadiazol-2-yl]-1- (biphenyl-4-yl) propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem . 2009 Sep;44 (9) :3798-804.|[5]Christina E Smith, et al. Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors. Cell Chem Biol. 2017 Mar 16;24 (3) :281-292.|[6]R M Palmer, et al. Effects of the cyclo-oxygenase inhibitor, fenbufen, on clenbuterol-induced hypertrophy of cardiac and skeletal muscle of rats. Br J Pharmacol. 1990 Dec;101 (4) :835-8.